The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the accelerating pace of innovation in the health-tech sector, DexCom's over-the-counter (OTC) continuous glucose monitor, Stelo, has received approval for pediatric use. According to reports, this regulatory milestone allows younger populations to access glucose monitoring technology without a prescription. The expansion aims to bolster the company's market share by targeting a broader user base beyond the adult demographic.
This expansion comes amid intensifying competition with Abbott Laboratories, which recently secured FDA clearances for its Lingo and Libre Rio OTC systems, according to Seeking Alpha reports. DexCom remains a pioneer in the space, having been the first to launch a direct-to-consumer CGM in the U.S. last summer. Analysts suggest that the market for glucose monitoring among non-insulin users represents a multi-billion dollar growth opportunity, per market data.
Sign in to access this content
Sign InRegarding market performance, DXCM stock closed at $75.25 (close June 11, 2026), trading within a daily range of $74.04 to $76.03 per market data. Investors are closely monitoring how this pediatric expansion will impact profit margins in upcoming quarters. Looking at the economic calendar, while there are no sector-specific catalysts in the next seven days, markets remain attentive to Fed official speeches that could influence growth-oriented stocks.